NASDAQ:CYTH Cyclo Therapeutics (CYTH) Stock Price, News & Analysis $0.75 +0.03 (+4.18%) (As of 10/31/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Cyclo Therapeutics Stock (NASDAQ:CYTH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Cyclo Therapeutics alerts:Sign Up Key Stats Today's Range$0.71▼$0.7550-Day Range$0.64▼$0.9252-Week Range$0.59▼$2.12Volume5,992 shsAverage Volume71,378 shsMarket Capitalization$21.46 millionP/E RatioN/ADividend YieldN/APrice Target$0.95Consensus RatingHold Company OverviewCyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.Read More… Urgent: This election is rigged (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Cyclo Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks70th Percentile Overall ScoreCYTH MarketRank™: Cyclo Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 359th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCyclo Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCyclo Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cyclo Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Cyclo Therapeutics are expected to decrease in the coming year, from ($0.72) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cyclo Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cyclo Therapeutics is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCyclo Therapeutics has a P/B Ratio of 3.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Cyclo Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.79% of the float of Cyclo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclo Therapeutics has recently decreased by 21.95%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCyclo Therapeutics does not currently pay a dividend.Dividend GrowthCyclo Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.79% of the float of Cyclo Therapeutics has been sold short.Short Interest Ratio / Days to CoverCyclo Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cyclo Therapeutics has recently decreased by 21.95%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.43 News SentimentCyclo Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Cyclo Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added Cyclo Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cyclo Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders29.78% of the stock of Cyclo Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.55% of the stock of Cyclo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cyclo Therapeutics' insider trading history. Receive CYTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cyclo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CYTH Stock News HeadlinesPacira BioSciences Appoints Shawn Cross As CFOOctober 21, 2024 | markets.businessinsider.comMaxim Group Downgrades Cyclo Therapeutics (CYTH)August 29, 2024 | msn.comEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now.October 31, 2024 | Paradigm Press (Ad)CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTHAugust 27, 2024 | businesswire.comHC Wainwright & Co. Downgrades Cyclo Therapeutics (CYTH)August 24, 2024 | msn.comShareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public ShareholdersAugust 23, 2024 | prnewswire.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Cyclo Therapeutics, Inc. MergerAugust 22, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTHAugust 22, 2024 | prnewswire.comSee More Headlines CYTH Stock Analysis - Frequently Asked Questions How have CYTH shares performed this year? Cyclo Therapeutics' stock was trading at $1.59 at the start of the year. Since then, CYTH shares have decreased by 53.0% and is now trading at $0.7480. View the best growth stocks for 2024 here. How were Cyclo Therapeutics' earnings last quarter? Cyclo Therapeutics, Inc. (NASDAQ:CYTH) posted its quarterly earnings data on Thursday, August, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by $0.07. The company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.40 million. Cyclo Therapeutics had a negative trailing twelve-month return on equity of 2,741.89% and a negative net margin of 1,830.27%. How do I buy shares of Cyclo Therapeutics? Shares of CYTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cyclo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cyclo Therapeutics investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Ford Motor (F), Alphabet (GOOG), Cassava Sciences (SAVA), Zoom Video Communications (ZM) and Fisker (FSR). Company Calendar Last Earnings8/15/2024Today10/31/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CYTH CUSIPN/A CIK922247 Webwww.ctd-holdings.com Phone(386) 418-8060Fax321-244-8351Employees9Year FoundedN/APrice Target and Rating Average Stock Price Target$0.95 High Stock Price Target$0.95 Low Stock Price Target$0.95 Potential Upside/Downside+27.5%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,060,000.00 Net Margins-1,830.27% Pretax Margin-1,830.36% Return on Equity-2,741.89% Return on Assets-269.95% Debt Debt-to-Equity RatioN/A Current Ratio0.45 Quick Ratio0.43 Sales & Book Value Annual Sales$1.13 million Price / Sales18.88 Cash FlowN/A Price / Cash FlowN/A Book Value$0.21 per share Price / Book3.55Miscellaneous Outstanding Shares28,696,000Free Float20,150,000Market Cap$21.38 million OptionableNo Data Beta-0.38 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:CYTH) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.